For the quarter ending 2025-03-31.
| Income Statement | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Research and development | 369 | 3,163 | ||
| General and administrative | 2,405 | 5,189 | ||
| Total operating expenses | 2,774 | 8,352 | ||
| (loss) income from operations | -2,774 | -8,352 | ||
| Other expense, net | -1 | -10 | ||
| Interest and dividend income | 202 | 355 | ||
| Total other income, net | 201 | 345 | ||
| Net (loss) income | -2,573 | -8,007 | ||
| Basic EPS | -0.39 | -1.2 | ||
| Diluted EPS | -0.39 | -1.2 | ||
| Basic Average Shares | 6,663,000 | 6,663,000 | ||
| Diluted Average Shares | 6,663,000 | 6,663,000 | ||
MEI Pharma, Inc. (MEIP)
MEI Pharma, Inc. (MEIP)